Gedeon Richter PLC (GEDSF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Gedeon Richter PLC (GEDSF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 53/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Gedeon Richter PLC (GEDSF) Resumen de Asistencia Médica y Tuberías
Gedeon Richter PLC, founded in 1901, is a Hungary-based pharmaceutical company focused on developing, manufacturing, and marketing pharmaceutical products. Operating through pharmaceutical, wholesale & retail, and other segments, the company boasts a 25% profit margin and a 4.28% dividend yield, positioning it as a key player in the European pharmaceutical landscape.
Tesis de Inversión
Gedeon Richter PLC presents a compelling investment case based on its established market position, consistent profitability, and attractive dividend yield of 4.28%. The company's diversified product portfolio and expanding presence in key therapeutic areas like gynecology and central nervous system disorders drive revenue growth. With a P/E ratio of 9.34 and a profit margin of 25.0%, GEDSF demonstrates financial stability. Upcoming catalysts include potential regulatory approvals for pipeline products and expansion into new markets. Potential risks include increased competition from generic manufacturers and regulatory challenges. The company's commitment to R&D and strategic partnerships positions it for sustained growth in the pharmaceutical sector.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $4.54 billion, reflecting substantial investor confidence.
- P/E ratio of 9.34, indicating a potentially undervalued stock compared to industry peers.
- Profit margin of 25.0%, showcasing efficient operations and strong pricing power.
- Gross margin of 68.1%, highlighting the company's ability to control production costs and maintain profitability.
- Dividend yield of 4.28%, providing a significant income stream for investors.
Competidores y Pares
Fortalezas
- Established presence in Central and Eastern Europe.
- Diversified product portfolio across multiple therapeutic areas.
- Strong research and development capabilities.
- Consistent profitability and dividend payments.
Debilidades
- Reliance on generic drug sales, which are subject to price erosion.
- Limited presence in major Western markets.
- Exposure to regulatory risks and patent challenges.
- Dependence on a limited number of key products.
Catalizadores
- Upcoming: Potential regulatory approvals for pipeline products in key therapeutic areas.
- Ongoing: Expansion of biosimilar portfolio to capture market share from expiring patents.
- Ongoing: Strategic partnerships and acquisitions to enhance product pipeline and market reach.
- Ongoing: Geographic expansion in emerging markets with high growth potential.
- Ongoing: Investment in research and development to create novel therapies for unmet medical needs.
Riesgos
- Potential: Increased competition from generic drug manufacturers, leading to price erosion.
- Potential: Regulatory challenges and pricing pressures in key markets.
- Potential: Patent expirations and loss of exclusivity on key products.
- Ongoing: Economic downturns and healthcare reforms that could impact demand.
- Ongoing: Fluctuations in currency exchange rates, affecting revenue and profitability.
Oportunidades de crecimiento
- Expanding Biosimilar Portfolio: Gedeon Richter has the opportunity to capitalize on the growing biosimilars market, driven by patent expirations of blockbuster drugs. The global biosimilars market is projected to reach hundreds of billions of dollars by 2030. By investing in the development and commercialization of biosimilars, Gedeon Richter can capture a significant share of this market, offering cost-effective alternatives to expensive branded biologics. This strategy aligns with the global trend towards reducing healthcare costs and increasing access to essential medicines.
- Strategic Partnerships and Acquisitions: Gedeon Richter can enhance its product pipeline and market reach through strategic partnerships and acquisitions. Collaborating with biotechnology companies and research institutions can provide access to innovative technologies and novel drug candidates. Acquiring smaller pharmaceutical companies with complementary product portfolios can expand Gedeon Richter's therapeutic areas and geographic presence. These strategic moves can accelerate growth and diversify revenue streams.
- Geographic Expansion in Emerging Markets: Gedeon Richter has the opportunity to expand its presence in emerging markets, where healthcare spending is rapidly increasing. Countries in Asia, Latin America, and Africa offer significant growth potential due to their large populations and unmet medical needs. By establishing local manufacturing facilities and distribution networks, Gedeon Richter can gain a competitive advantage and capture a larger share of these markets. This expansion strategy can drive long-term revenue growth and reduce reliance on mature markets.
- Focus on Women's Healthcare: Gedeon Richter has a strong presence in women's healthcare, particularly in gynecology. The company can further strengthen its position by developing and commercializing innovative products for women's health needs, such as contraception, fertility treatments, and menopause management. The global market for women's healthcare products is substantial and growing, driven by increasing awareness of women's health issues and advancements in medical technology. By focusing on this specialized area, Gedeon Richter can differentiate itself and build a loyal customer base.
- Investment in Research and Development: Gedeon Richter's commitment to research and development is crucial for its long-term growth. By investing in innovative drug discovery and development programs, the company can create novel therapies for unmet medical needs. Focusing on areas such as central nervous system disorders, oncology, and autoimmune diseases can lead to the development of blockbuster drugs and generate significant revenue. A strong R&D pipeline is essential for sustaining growth and maintaining a competitive edge in the pharmaceutical industry.
Oportunidades
- Expansion into emerging markets with high growth potential.
- Development and commercialization of biosimilars.
- Strategic partnerships and acquisitions to expand product pipeline.
- Increased focus on specialty pharmaceuticals and innovative therapies.
Amenazas
- Intense competition from generic drug manufacturers.
- Stringent regulatory requirements and pricing pressures.
- Patent expirations and loss of exclusivity on key products.
- Economic downturns and healthcare reforms that could impact demand.
Ventajas competitivas
- Strong brand recognition in Central and Eastern Europe.
- Extensive distribution network across multiple countries.
- Portfolio of both generic and branded pharmaceutical products.
- Commitment to research and development, leading to innovative products.
Acerca de GEDSF
Chemical Works of Gedeon Richter Plc, established in 1901 by Gedeon Richter in Budapest, Hungary, is a pharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical products. Initially focused on producing organotherapeutic pharmaceuticals, the company expanded its portfolio to include a wide range of therapeutic areas, such as gynecology, cardiology, and central nervous system disorders. Over the years, Gedeon Richter has grown from a local Hungarian manufacturer to an international player with a presence in over 100 countries. The company operates through three primary segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment is involved in the core activities of research and development, manufacturing, sales, and marketing of pharmaceutical products. The Wholesale & Retail segment manages the distribution network through companies and pharmacies, ensuring its products reach consumers in various regional markets. The Other segment provides marketing and sales support services. Gedeon Richter's product portfolio includes original research products, generic medicines, and biosimilars. Its commitment to innovation and strategic partnerships has enabled it to maintain a competitive edge in the global pharmaceutical market. The company's headquarters remain in Budapest, reflecting its deep roots in Hungarian pharmaceutical history.
Qué hacen
- Develops and manufactures pharmaceutical products.
- Engages in research and development activities.
- Markets and sells pharmaceutical products globally.
- Distributes products through wholesale and retail channels.
- Provides marketing and sales support services.
- Focuses on therapeutic areas such as gynecology, cardiology, and central nervous system disorders.
Modelo de Negocio
- Develops and manufactures a range of pharmaceutical products, including generic medicines, original research products, and biosimilars.
- Sells its products through a combination of direct sales, wholesale distributors, and retail pharmacies.
- Generates revenue from the sale of pharmaceutical products in various regional markets.
Contexto de la Industria
Gedeon Richter PLC operates within the global pharmaceutical industry, a sector characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. Gedeon Richter competes with both multinational pharmaceutical giants and generic drug manufacturers. The company's focus on specialty pharmaceuticals and biosimilars allows it to differentiate itself in a crowded market. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, offering significant growth opportunities for companies like Gedeon Richter.
Clientes Clave
- Patients who require pharmaceutical treatments.
- Hospitals and clinics that purchase medications for their patients.
- Pharmacies that dispense medications to consumers.
- Wholesale distributors that supply medications to pharmacies and hospitals.
Finanzas
Gráfico e información
Precio de la acción de Gedeon Richter PLC (GEDSF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para GEDSF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GEDSF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GEDSF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GEDSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Gabor Orban
CEO
Gabor Orban serves as the CEO of Gedeon Richter PLC, leading a workforce of over 10,000 employees. His career spans several decades in the pharmaceutical industry, with a focus on strategic management and international expansion. He holds advanced degrees in economics and business administration, providing a strong foundation for his leadership role. Prior to becoming CEO, Orban held various executive positions within Gedeon Richter, overseeing areas such as sales, marketing, and business development. His experience includes navigating complex regulatory environments and driving growth in both established and emerging markets.
Historial: Under Gabor Orban's leadership, Gedeon Richter has expanded its global presence and strengthened its position in key therapeutic areas. He has overseen the launch of several successful products and implemented strategic initiatives to improve operational efficiency. Key milestones include the expansion of the biosimilar portfolio and the establishment of new partnerships to enhance research and development capabilities. Orban's focus on innovation and international growth has contributed to the company's sustained profitability and market leadership.
Información del mercado OTC de GEDSF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Gedeon Richter PLC (GEDSF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited information available to investors, and trading activity can be sporadic. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier are not subject to the same rigorous listing standards, potentially increasing investment risk.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining reliable information about the company's operations and financial condition.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings involving the company.
- The company has been in operation for over a century, indicating a long-term presence in the pharmaceutical industry.
- Gedeon Richter has a significant number of employees, suggesting a substantial operational scale.
- The company has a diversified product portfolio and a presence in multiple regional markets.
- Gedeon Richter has a history of paying dividends, demonstrating a commitment to shareholder returns.
- The company is headquartered in Budapest, Hungary, a country with a well-established pharmaceutical industry.
Acciones de Gedeon Richter PLC: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar GEDSF?
Gedeon Richter PLC (GEDSF) actualmente tiene una puntuación IA de 53/100, indicando puntuación moderada. Fortaleza clave: Established presence in Central and Eastern Europe.. Riesgo principal a monitorear: Potential: Increased competition from generic drug manufacturers, leading to price erosion.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GEDSF?
GEDSF actualmente puntúa 53/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GEDSF?
Los precios de GEDSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GEDSF?
La cobertura de analistas para GEDSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GEDSF?
Las categorías de riesgo para GEDSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Increased competition from generic drug manufacturers, leading to price erosion.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GEDSF?
La relación P/E para GEDSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GEDSF sobrevalorada o infravalorada?
Determinar si Gedeon Richter PLC (GEDSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GEDSF?
Gedeon Richter PLC (GEDSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited analyst coverage due to OTC listing.
- Financial data based on available public information.
- OTC market investments carry additional risks.